Collegium Pharmaceutical Announces Series B Financing and Advancement of Development Program for its DETERx® Tamper-Resistant, Extended-Release Opioid

CUMBERLAND, R.I.--(BUSINESS WIRE)--Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, announced today that it has raised $22.5 million in a Series B financing round led by Longitude Capital and Skyline Ventures. Series A investors Frazier Healthcare Ventures and Boston Millennia Partners also participated in the round. In connection with the financing, David Hirsch, MD, PhD of Longitude Capital and Stephen Hoff

Feed Date: 
February 22, 2012